• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

羧基末端结构域的自动磷酸化对于肺癌衍生的 EGFR 突变体的致癌转化不是必需的。

Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.

机构信息

Department of Nanobiomedical Science, Dankook University, Cheonan, 31116, Republic of Korea.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115.

出版信息

Int J Cancer. 2018 Aug 1;143(3):679-685. doi: 10.1002/ijc.31332. Epub 2018 Mar 5.

DOI:10.1002/ijc.31332
PMID:29464683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6033109/
Abstract

Aberrant activation of cancer-derived mutants of the epidermal growth factor receptor (EGFR) is closely associated with cancer pathogenesis and is thought to be mediated through multiple tyrosine phosphorylations within the C-terminal domain. Here, we examined the consequences of the loss of these C-terminal phosphorylation sites on cellular transformation in the context of lung-cancer-derived L858R, exon 19 deletion and exon 20 insertion mutant EGFR. Oncogenic EGFR mutants with substitution of the 10 potential C-terminal tyrosine autophosphorylation sites for phenylalanine (CYF10) were still able to promote anchorage-independent growth in soft agar at levels comparable to the parental L858R or exon19 deletion or exon 20 insertion mutants with intact autophosphorylation sites. Furthermore, these CYF10 mutants retained the ability to transform Ba/F3 cells in the absence of IL-3. Bead-based phosphorylation and immunoprecipitation analyses demonstrated that key EGFR-associated proteins-including Grb2 and PLC-γ-are neither phosphorylated nor bound to CYF10 mutants in transformed cells. Taken together, we conclude that tyrosine phosphorylation is not required for oncogenic activity of lung-cancer-derived mutant EGFR, suggesting these mutants can lead to cellular transformation by an alternative mechanism independent of EGFR phosphorylation.

摘要

致癌突变体表皮生长因子受体(EGFR)的异常激活与癌症发病机制密切相关,被认为是通过 C 末端结构域内的多个酪氨酸磷酸化介导的。在这里,我们研究了在肺癌衍生的 L858R、外显子 19 缺失和外显子 20 插入突变 EGFR 背景下,这些 C 末端磷酸化位点缺失对细胞转化的影响。具有 10 个潜在 C 末端酪氨酸自身磷酸化位点突变为苯丙氨酸(CYF10)的致癌 EGFR 突变体仍然能够在软琼脂中促进无锚定依赖性生长,其水平与具有完整自身磷酸化位点的亲本 L858R 或外显子 19 缺失或外显子 20 插入突变体相当。此外,这些 CYF10 突变体在没有 IL-3 的情况下仍然保留转化 Ba/F3 细胞的能力。基于珠的磷酸化和免疫沉淀分析表明,包括 Grb2 和 PLC-γ 在内的关键 EGFR 相关蛋白在转化细胞中既不被磷酸化也不与 CYF10 突变体结合。综上所述,我们得出结论,酪氨酸磷酸化不是肺癌衍生的突变型 EGFR 致癌活性所必需的,这表明这些突变体可以通过独立于 EGFR 磷酸化的替代机制导致细胞转化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b28/6033109/15586e942022/IJC-143-679-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b28/6033109/01c166e1fe18/IJC-143-679-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b28/6033109/65ff073cedc4/IJC-143-679-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b28/6033109/15586e942022/IJC-143-679-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b28/6033109/01c166e1fe18/IJC-143-679-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b28/6033109/65ff073cedc4/IJC-143-679-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b28/6033109/15586e942022/IJC-143-679-g003.jpg

相似文献

1
Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.羧基末端结构域的自动磷酸化对于肺癌衍生的 EGFR 突变体的致癌转化不是必需的。
Int J Cancer. 2018 Aug 1;143(3):679-685. doi: 10.1002/ijc.31332. Epub 2018 Mar 5.
2
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.肺癌衍生表皮生长因子受体突变体对西妥昔单抗的反应与非对称二聚化有关。
Cancer Res. 2013 Nov 15;73(22):6770-9. doi: 10.1158/0008-5472.CAN-13-1145. Epub 2013 Sep 24.
3
HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling.HER2 通过改变自身的自动磷酸化模式来稳定 EGFR 及其自身,这种方式克服了调节机制,促进了增殖和转化信号转导。
Oncogene. 2013 Aug 29;32(35):4169-80. doi: 10.1038/onc.2012.418. Epub 2012 Oct 1.
4
Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.组成型不对称二聚化驱动表皮生长因子受体羧基末端缺失突变体的致癌激活。
Oncotarget. 2015 Apr 20;6(11):8839-50. doi: 10.18632/oncotarget.3559.
5
A carboxyl-terminal mutation of the epidermal growth factor receptor alters tyrosine kinase activity and substrate specificity as measured by a fluorescence polarization assay.
J Biol Chem. 2003 Jul 18;278(29):26810-6. doi: 10.1074/jbc.M301397200. Epub 2003 May 12.
6
The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants.Src协同作用在非小细胞肺癌相关表皮生长因子受体突变介导的致癌转化中的作用
Oncogene. 2009 Apr 23;28(16):1821-32. doi: 10.1038/onc.2009.31. Epub 2009 Mar 23.
7
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.癌症来源的表皮生长因子受体突变体对Ba/F3细胞进行不依赖表皮生长因子的转化可诱导吉非替尼敏感的细胞周期进程。
Cancer Res. 2005 Oct 1;65(19):8968-74. doi: 10.1158/0008-5472.CAN-05-1829.
8
Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu.Shc蛋白的酪氨酸磷酸化以及Shc/Grb2复合物的形成与点突变激活的neu介导的NIH3T3细胞转化相关。
Oncogene. 1995 Jun 15;10(12):2409-13.
9
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.多种致癌性改变(K-RAS(V12)、p53基因敲低、突变型表皮生长因子受体、p16基因旁路、端粒酶)并不足以使人支气管上皮细胞呈现完全的恶性表型。
Cancer Res. 2006 Feb 15;66(4):2116-28. doi: 10.1158/0008-5472.CAN-05-2521.
10
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.建立对吉非替尼耐药的人非小细胞肺癌细胞系。
Int J Cancer. 2005 Aug 10;116(1):36-44. doi: 10.1002/ijc.20985.

引用本文的文献

1
Multimodal scanning of genetic variants with base and prime editing.利用碱基编辑和引导编辑对基因变异进行多模态扫描。
Nat Biotechnol. 2024 Nov 12. doi: 10.1038/s41587-024-02439-1.
2
Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.鼻窦鳞状细胞癌中的外显子20插入突变
Cancers (Basel). 2022 Jan 13;14(2):394. doi: 10.3390/cancers14020394.
3
Tyrosine kinase-independent actions of DDR2 in tumor cells and cancer-associated fibroblasts influence tumor invasion, migration and metastasis.DDR2 在肿瘤细胞和肿瘤相关成纤维细胞中的酪氨酸激酶非依赖性作用影响肿瘤的侵袭、迁移和转移。

本文引用的文献

1
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.受突变驱动:EGFR 突变型非小细胞肺癌中突变亚型的预测价值。
J Thorac Oncol. 2017 Apr;12(4):612-623. doi: 10.1016/j.jtho.2016.12.014. Epub 2016 Dec 23.
2
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6.Mig6对表皮生长因子受体基于活性的抑制作用的结构与机制
Nat Struct Mol Biol. 2015 Sep;22(9):703-711. doi: 10.1038/nsmb.3074. Epub 2015 Aug 17.
3
Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
J Cell Sci. 2021 Oct 1;134(19). doi: 10.1242/jcs.258431. Epub 2021 Oct 13.
4
EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma.表皮生长因子受体(EGFR)DNA甲基化与肺腺癌中的EGFR表达、免疫细胞浸润及总生存期相关。
Front Oncol. 2021 Aug 10;11:691915. doi: 10.3389/fonc.2021.691915. eCollection 2021.
5
Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective.深入了解受体二聚化对致癌激活突变型 EGFR 的不同需求及其临床意义。
BMB Rep. 2020 Mar;53(3):133-141. doi: 10.5483/BMBRep.2020.53.3.025.
6
Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.基于其激酶非依赖性功能对癌症中表皮生长因子受体(EGFR)的重新思考
Front Oncol. 2019 Aug 23;9:800. doi: 10.3389/fonc.2019.00800. eCollection 2019.
7
Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.全转录组分析鉴定 TNS4 为西妥昔单抗的关键效应因子和 KRAS 突变型结直肠癌细胞系致癌活性的调节剂。
Cells. 2019 Aug 12;8(8):878. doi: 10.3390/cells8080878.
8
Defining molecular risk in ALK NSCLC.定义ALK非小细胞肺癌中的分子风险。
Oncotarget. 2019 May 3;10(33):3093-3103. doi: 10.18632/oncotarget.26886.
9
Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors.激酶失活的 EGFR 对于接受酪氨酸激酶抑制剂治疗的野生型 EGFR 表达癌细胞的存活是必需的。
Int J Mol Sci. 2019 May 22;20(10):2515. doi: 10.3390/ijms20102515.
组成型不对称二聚化驱动表皮生长因子受体羧基末端缺失突变体的致癌激活。
Oncotarget. 2015 Apr 20;6(11):8839-50. doi: 10.18632/oncotarget.3559.
4
A structural perspective on the regulation of the epidermal growth factor receptor.表皮生长因子受体调控的结构视角
Annu Rev Biochem. 2015;84:739-64. doi: 10.1146/annurev-biochem-060614-034402. Epub 2015 Jan 26.
5
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.表皮生长因子受体(EGFR)突变型肺腺癌中PI3K通路的ERBB3非依赖性激活
Cancer Res. 2015 Mar 15;75(6):1035-45. doi: 10.1158/0008-5472.CAN-13-1625. Epub 2015 Jan 16.
6
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.肺癌衍生表皮生长因子受体突变体对西妥昔单抗的反应与非对称二聚化有关。
Cancer Res. 2013 Nov 15;73(22):6770-9. doi: 10.1158/0008-5472.CAN-13-1145. Epub 2013 Sep 24.
7
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.表皮生长因子受体变体 III(EGFRvIII):野生之物的改变之处。
FEBS J. 2013 Nov;280(21):5350-70. doi: 10.1111/febs.12393. Epub 2013 Jul 8.
8
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.大规模平行测序绘制肺腺癌特征图谱。
Cell. 2012 Sep 14;150(6):1107-20. doi: 10.1016/j.cell.2012.08.029.
9
The ERBB network: at last, cancer therapy meets systems biology.ERBB 网络:癌症治疗终于迎来了系统生物学。
Nat Rev Cancer. 2012 Jul 12;12(8):553-63. doi: 10.1038/nrc3309.
10
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.胶质母细胞瘤衍生的表皮生长因子受体羧基末端缺失突变体具有转化能力,并对 EGFR 靶向治疗敏感。
Cancer Res. 2011 Dec 15;71(24):7587-96. doi: 10.1158/0008-5472.CAN-11-0821. Epub 2011 Oct 14.